Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01928290 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer
A Phase 2 study of Esophageal Neoplasms and Stomach Neoplasms, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 1
- Study location
NCT01928290 is a Phase 2 study of Esophageal Neoplasms and Stomach Neoplasms that has completed, run by Washington University School of Medicine. The registered enrollment target is 67 participants, below the 1,483-participant average among 12 other Esophageal Neoplasms trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01928290, a Phase 2 study of Esophageal Neoplasms and Stomach Neoplasms, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well combination chemotherapy works in treating patients with advanced stomach, gastroesophageal, or esophageal cancer. Drugs used in chemotherapy, such as irinotecan hydrochloride, oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Fluorouracil
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG Irinotecan
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2013-11-08 |
| Est. Completion | 2019-10-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01928290
The ClinicalTrials.gov registry entry for NCT01928290 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,483-participant average among 12 other Esophageal Neoplasms trials with a reported enrollment target (95% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Esophageal Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.
NCT01928290 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT01928290 about?
NCT01928290 is a clinical study titled "Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer". This phase II trial studies how well combination chemotherapy works in treating patients with advanced stomach, gastroesophageal, or esophageal cancer. Drugs used in chemotherapy, such as irinotecan hydrochloride, oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the ...
What is the current status of trial NCT01928290?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2013-11-08. Estimated completion is 2019-10-28.
What conditions does trial NCT01928290 study?
This clinical trial studies the following conditions: Esophageal Neoplasms, Stomach Neoplasms.
What interventions are being tested in trial NCT01928290?
The interventions under investigation include: Trastuzumab (DRUG), Fluorouracil (DRUG), Leucovorin (DRUG), Oxaliplatin (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT01928290?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01928290 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
COMPLETED · Phase 2
-
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
COMPLETED · Phase 2
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
RECRUITING
-
Mayo Clinic Upper Digestive Disease Survey
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.